<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The presence of moderate to severe bone marrow (BM) <z:mp ids='MP_0003045'>fibrosis</z:mp> has been shown to be an adverse feature in patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the clinical importance of BM <z:mp ids='MP_0003045'>fibrosis</z:mp> is not clear in <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We retrieved <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) cases (n = 266) diagnosed at our hospital over a 10-year period (2003-2012) </plain></SENT>
<SENT sid="3" pm="."><plain>Reticulin and trichrome stains were performed in cases in which BM <z:mp ids='MP_0003045'>fibrosis</z:mp> was suspected on initial evaluation of <z:chebi fb="1" ids="51686">hematoxylin</z:chebi> and eosin-stained slide </plain></SENT>
<SENT sid="4" pm="."><plain>BM <z:mp ids='MP_0003045'>fibrosis</z:mp> was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Moderate/severe BM <z:mp ids='MP_0003045'>fibrosis</z:mp> was found in 47 (17 %) patients </plain></SENT>
<SENT sid="6" pm="."><plain>Compared to 219 patients with no/mild BM <z:mp ids='MP_0003045'>fibrosis</z:mp>, the patients with moderate/severe <z:mp ids='MP_0003045'>fibrosis</z:mp> presented with severer <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, transfusion requirements, and similar incidences of <z:hpo ids='HP_0001433'>hepatosplenomegaly</z:hpo> and constitutional symptoms </plain></SENT>
<SENT sid="7" pm="."><plain>Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p &lt; 0.001) in the fibrotic group </plain></SENT>
<SENT sid="8" pm="."><plain>Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, -5 and -17 were more frequently observed in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with moderate/severe BM <z:mp ids='MP_0003045'>fibrosis</z:mp> (p = 0.031 and p = 0.043, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>With a median follow-up of 11.5 months, patients with moderate/severe BM <z:mp ids='MP_0003045'>fibrosis</z:mp> showed a similar risk of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> transformation and a comparable overall survival in univariate and multivariate analyses </plain></SENT>
<SENT sid="10" pm="."><plain>Moderate/severe BM <z:mp ids='MP_0003045'>fibrosis</z:mp> in patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is associated with certain clinicopathological and genetic features </plain></SENT>
<SENT sid="11" pm="."><plain>However, unlike the situation in patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, moderate/severe BM <z:mp ids='MP_0003045'>fibrosis</z:mp> does not add additional risk to patients with <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> </plain></SENT>
</text></document>